Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Gilead advances ADC dreams with potential $465M deal
Gilead is paying Munich-based biotech Tubulis $20M upfront, with the chance of a $30M option and up to $415M in milestone payments.
Darren Incorvaia
Dec 3, 2024 10:54am
Gilead buys HIV vaccine from biotech following clinical collab
Nov 25, 2024 10:30am
Gilead to lay off 72 staffers, shutter Seattle R&D office
Nov 14, 2024 1:09pm
ASH: Gilead-Arcellx data build CAR-T's case in advanced myeloma
Nov 5, 2024 3:08pm
Arcus drops promising data on HIF-2a candidate in kidney cancer
Oct 24, 2024 2:48pm
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
Oct 21, 2024 5:06am
